HSIC vs LAB · P/E 24, rev $12.67B vs rev $174.4M
Henry Schein Inc (HSIC) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. LAB currently screens at market cap $317.1M.
Not investment advice. Open the HSIC and LAB stock pages for the full models.
Not investment advice.